| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/29/2010 | US7745457 Meridamycin analogues for the treatment of neurodegenerative disorders |
| 06/29/2010 | US7745456 2,5-bis{[alkyl(or aryl)imino]aminophenyl}furans and thiophenes; "reversed" amidines; DNA-binding affinities; microbiocide; mycobacterial, fungal, protozoal infection; Mycobacterium tuberculosis, Trypanosoma spp., Candida albicans, Aspergillus spp., Cryptosporidium parvum, Giardia lamblia, Plasmodium spp. |
| 06/29/2010 | US7745455 Administrating a first cytidine analogue reverse transcriptase inhibitor concurrently with deoxycytidine; increasing the antiretroviral activity of the first analogue; HIV treatment |
| 06/29/2010 | US7745454 Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
| 06/29/2010 | US7745453 Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase |
| 06/29/2010 | US7745450 5-[1-(hydroxymethyl)propyl]amino-7-benzylamino-3-isopropyl(methyl, ethyl)pyrazolo[4,3-d]pyrimidine for inhibiting cell proliferation, cancer, or psoriasis, rheumatoid arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, and neurodegerative diseases |
| 06/29/2010 | US7745449 Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
| 06/29/2010 | US7745448 Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate |
| 06/29/2010 | US7745447 6-(4-Chlorophenyl)-3-(5-hydroxypyridin-2-yl)thieno[3,2-d]pyrimidin-4(3H)-one, for example; for treating a patient suffering from an MCHR-1 modulated disease or disorder such as obesity, diabetes, depression or anxiety |
| 06/29/2010 | US7745446 such as 4-Aminomethyl-N-[4-(5-biphenyl-4-yl-pyrazolo[1,5-c]pyrimidin-7-ylamino)-phenyl]-benzamide, useful in the therapy of (hyper)proliferative diseases and/or disorders responsive to induction of apoptosis |
| 06/29/2010 | US7745445 Compounds and compositions as PPAR modulators |
| 06/29/2010 | US7745444 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| 06/29/2010 | US7745442 Methods of reducing risk of infection from pathogens |
| 06/29/2010 | US7745441 Urokinase inhibitors |
| 06/29/2010 | US7745440 Pyrazole analogs acting on cannabinoid receptors |
| 06/29/2010 | US7745439 Indene derivatives and process for the preparation thereof |
| 06/29/2010 | US7745438 beta -secretase inhibitors such as N-{(1S,2S)-1-(3,5-Difluorobenzyl)-2-[(3R,5S,6R)-6-(2,2-dimethylpropoxy)-5-methylmorpholin-3-yl]-2-hydroxyethyl}-acetamide, used for the treatment of neurodegenerative disorders such as Alzheimer's disease |
| 06/29/2010 | US7745437 Compounds and compositions as protein kinase inhibitors |
| 06/29/2010 | US7745436 Disalt inhibitors of IL-12 production |
| 06/29/2010 | US7745434 1-[4-(4-amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)phenyl]-3-(5-tert-butylisoxazol-3-yl)urea; treatment of tyrosine kinase-induced diseases and conditions, such as angiogenesis, cancer, tumour formation, growth and propagation, arteriosclerosis, ocular diseases, such as age-induced macular degeneration |
| 06/29/2010 | US7745433 2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2, 3-D] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof |
| 06/29/2010 | US7745432 4-[4-(4-cyano-benzoyl)-1,9b-dihydro-5-oxa-3,3a-diaza-cyclopenta[a]naphthalen-2-yl]-N,N-diethyl-benzylamine, used for treating viral diseases selected from Acquired Immune Deficiency Syndrome (AIDS), progressive generalized lymphadenopathy (PGL), HIV-mediated dementia and multiple sclerosis |
| 06/29/2010 | US7745431 leukotriene B4 inhibitor; optically pure R-enantionmer of tofisopam |
| 06/29/2010 | US7745430 Comprising diazepam as an active ingredient, water, a fatty acid ester, diethylene glycol monoethyl ether, ethanol and sodium glycocholate, wherein the weight of the fatty acid ester is at least 2-fold higher than that of water and at least 2-fold higher than that of ethanol; epilepsy treatment |
| 06/29/2010 | US7745429 Crystal forms of olanzapine and processes for their preparation |
| 06/29/2010 | US7745428 [4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-morpholin-4-yl-methanone, used for treating rheumatoid arthritis in mammals |
| 06/29/2010 | US7745427 (Calcitonin gene related peptide); azepinone ligands; 1-[(2-methoxyethyl)-2-oxo-6-phenylazepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide; analgesic, antiinflammatory agent; migranes, arthritis, neurodegenerative diseases |
| 06/29/2010 | US7745426 vitamin B6-based component selected from pyridoxal, pyridoxamine or pyridoxine chemically linked to antiepileptic agents, neuroprotectants, neurotransmitters or nootropic agents, used for the treatment of epilepsy |
| 06/29/2010 | US7745425 Mixture containing water soluble zinc salt, water insoluble zinc salt, pantothenic acid and glycerin; antiseptic soap; surgery hand wash |
| 06/29/2010 | US7745424 Osteoporosis, bone cancer; antiarthritic agents;paget's disease; antiinflammatory agents |
| 06/29/2010 | US7745423 Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin |
| 06/29/2010 | US7745422 Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| 06/29/2010 | US7745421 Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells |
| 06/29/2010 | US7745420 stability, high effectiveness and low toxicity; for treating pulmonary/respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis |
| 06/29/2010 | US7745419 Short interfering RNAs (siRNA) against Wnt1; anticancer; drug delivery system of cationic liposome or cationic polymer |
| 06/29/2010 | US7745418 Compositions and methods for inhibiting viral replication |
| 06/29/2010 | US7745417 1,2-dihydro-2-pyridinone substituted with biotin, bromine or iodine photoreactive group, fluorescent molecule; artificial base pairs; aptamers, antisense agents, ribozymes |
| 06/29/2010 | US7745416 Method for in vivo regulation of cardiac muscle contractility |
| 06/29/2010 | US7745415 Modulate immune cytokine activities; treat hepatitis C virus infection; mask active structure as the agent passes through lymphoid tissue lining the stomach, minimizing activation of this tissue and allowing for improved oral tolerability |
| 06/29/2010 | US7745413 Collection of traceable compounds and uses thereof |
| 06/29/2010 | US7745406 Kit which determines concentration of phosphate metabolizing protein and utilizes profile as indicator of hypo/hyperphosphatemic disorders |
| 06/29/2010 | US7745392 Core moiety such as 1,4,8,11-tetraazacyclotetradecane with a plurality of side chains containing guanidinium groups; conjugated to antigens, peptides, tumor antigens, anticancer agents, antimicrobials |
| 06/29/2010 | US7745198 producing the 12-membered ring macrolide compound 11107D having an antitumor activity by biological transformation using genus Mortierella, the genus Streptomyces or the family Micromonosporaceae |
| 06/29/2010 | US7745114 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 06/29/2010 | US7745109 Regulation of cell growth by MUC1 |
| 06/29/2010 | US7744935 Compositions and methods for inhibiting 5-α reductase |
| 06/29/2010 | US7744930 Powdered shake mix for example; combinations of soy protein, chromium and free leucine among other vitamins, plant extracts and minerals; inhibit the loss of lean body mass |
| 06/29/2010 | US7744921 Liposome loading with metal ions |
| 06/29/2010 | US7744920 Glucocoricoid is an amphipathic weak acid or base such as methylprednisolone sodium hemisuccinate encapsulated in a liposome; treating rheumatoid arthritis or other autoimmune disease, provided they are not neurodegenerative disorders |
| 06/29/2010 | US7744919 Block copolymer micelle composition having an enhanced drug-loading capacity and sustained release |
| 06/29/2010 | US7744910 Compounds and compositions for delivering active agents |
| 06/29/2010 | US7744909 Dispersions for the formulation of slightly or poorly soluble agents |
| 06/29/2010 | US7744907 Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method |
| 06/29/2010 | US7744903 Epitopes confirmed to be recognized by T-cells derived from herpetic lesions or uterine cervix; vaccination; host cells |
| 06/29/2010 | US7744889 (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents |
| 06/29/2010 | US7744880 cell proliferation-inhibiting activity by ADCC (antibody-dependent cell-mediated cytotoxicity) activity and CDC (complement-dependent cytotoxicity); hepatic cancer |
| 06/29/2010 | US7744867 Anticancer, antitumor agents |
| 06/29/2010 | US7744861 Multi-arm polymer prodrugs |
| 06/29/2010 | US7744860 Reduced bioirritant composition |
| 06/29/2010 | US7744855 Milling particles for use in inhalable pharmaceuticals |
| 06/29/2010 | US7744854 Optimizing the regimen for administering anticarcinogenic and -tumor agents by administering methylselenocysteine and/or seleno-L-methionine which 'normalize' the existing vessels for better drug delivery; monitoring and upon detection of vessel maturation, administering a drug dose |
| 06/29/2010 | CA2575521C Medicinal composition containing diabetes remedy |
| 06/29/2010 | CA2557856C 3-'4-heterocyclyl-1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases |
| 06/29/2010 | CA2542007C Protein tyrosine kinase inhibitors |
| 06/29/2010 | CA2539541C Isoquinolinone potassium channel inhibitors |
| 06/29/2010 | CA2522053C Polymorphic form of montelukast sodium |
| 06/29/2010 | CA2504065C Dispersible antibacterial pharmaceutical compositions |
| 06/29/2010 | CA2474246C Alkylammonium salts of omeprazole and esomeprazole |
| 06/29/2010 | CA2461576C Process for the preparation of tablets comprising s-adenosylmethionine |
| 06/29/2010 | CA2455987C Tetrahydroindolone and purine derivatives linked to arylpiperazines |
| 06/29/2010 | CA2455628C Neuroprotective drug comprising flibanserin |
| 06/29/2010 | CA2453516C Alpha-ketoglutarates of l-carnitine and alkanoyl l-carnitine and compositions thereof |
| 06/29/2010 | CA2453117C Oral dosage forms comprising a benzimidazole and buffer |
| 06/29/2010 | CA2452471C Enhancement of transfection of dna into the liver |
| 06/29/2010 | CA2448273C Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| 06/29/2010 | CA2442885C Sulphones which modulate the action of gamma secretase |
| 06/29/2010 | CA2441696C Formulation to treat or prevent parasitic infection |
| 06/29/2010 | CA2426885C Complexes of phosphate derivatives |
| 06/29/2010 | CA2424596C Oral self-emulsifying formulations of pyranone protease inhibitors |
| 06/29/2010 | CA2417942C 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones |
| 06/29/2010 | CA2417923C Vaccination against host cell-associated herpesviruses |
| 06/29/2010 | CA2415280C Use of halogenated xanthenes as anti-cancer and anti-bacterial agents |
| 06/29/2010 | CA2409090C Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| 06/29/2010 | CA2406373C Controlled release paracetamol composition |
| 06/29/2010 | CA2405521C Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
| 06/29/2010 | CA2401942C Pharmaceutical compositions for buccal and pulmonary application |
| 06/29/2010 | CA2387746C Methods for stabilizing benzimidazole-based compounds |
| 06/29/2010 | CA2382885C Rhodamine derivatives for photodynamic diagnosis and treatment |
| 06/29/2010 | CA2382389C Pharmaceutically stable oxaliplatinum preparation for parenteral administration |
| 06/29/2010 | CA2379734C Treatment of cancers |
| 06/29/2010 | CA2373530C Taxane derivatives and processes for the preparation thereof |
| 06/29/2010 | CA2366765C Vacuolar-type (h+) -atpase-inhibiting compounds, compositions, and uses thereof |
| 06/29/2010 | CA2362051C Methods and compositions for use in perfusion applications |
| 06/29/2010 | CA2357114C Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| 06/29/2010 | CA2355814C Pharmaceutical composition for ophthalmic use |
| 06/29/2010 | CA2354557C Methods to inactivate n-type calcium channels |
| 06/29/2010 | CA2350396C A composition useful to treat periodontal disease |
| 06/29/2010 | CA2345985C Substituted 1,3-diaryl-2-pyrid-2-yl-3-(pyrid-2-ylamino)propanol derivatives,processes for their preparation, pharmaceuticals comprising these compounds and their use |
| 06/29/2010 | CA2336967C A3 adenosine receptor antagonists |
| 06/29/2010 | CA2336593C Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection |